4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid has been researched along with Reperfusion Injury in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaral, FA; Andrade, MV; Fagundes, CT; Ferreira, FL; Lisboa, RA; Souza, DG; Teixeira, MM; Trifilieff, A; Vieira, AT | 1 |
1 other study(ies) available for 4-aminobenzoyl-glycyl-prolyl-leucyl-alanine hydroxamic acid and Reperfusion Injury
| Article | Year |
|---|---|
Effects of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Capillary Permeability; Chemokines; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Hydroxamic Acids; Interleukin-10; Intestinal Mucosa; Intestines; Lung; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Oligopeptides; Reperfusion Injury; Survival Rate; Tumor Necrosis Factor-alpha | 2007 |